Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory GvHD: Clinical Responses and Long-Term Outcome. Stem Cells. 2015.
Increased EPO Levels Are Associated with Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells. J Bone Miner Res. 2016.
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv. 2018;2(16):2063-2071.
Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.
Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2020.
Clinical Implications of SRSF2 Mutations in AML Patients undergoing Allogeneic Stem Cell Transplantation. Am J Hematol. 2021.
Impact of PPM1D Mutations in Patients with Myelodysplastic Syndrome and Deletion of Chromosome 5q. Am J Hematol. 2021.
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol. 2022:JCO2200437.
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Ann Hematol. 2022.
Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2022.
Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission. Blood Adv. 2022..
Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies. Leukemia. 2022.
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12(12):170.